{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-236862","form_type":"8-K","ticker":"TCRX","cik":"0001783328","company_name":"TScan Therapeutics, Inc.","filed_at":"2026-05-22T20:05:44+00:00","discovered_at":"2026-05-22T20:08:00.346311+00:00","generated_at":"2026-05-22T21:12:07.552220+00:00","sec_items":["5.03","5.07","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.25,"confidence":"high","headline":"TScan Therapeutics stockholders approve doubling authorized shares to 600M and elect directors","bullets":["Katina Dorton (19.7M for) and R. Keith Woods (23.3M for) elected as Class II directors for three-year terms.","Deloitte & Touche ratified as independent auditor for fiscal year ending Dec 31, 2026 (38.5M for).","Amendment to increase authorized voting common stock from 300M to 600M shares approved (35.9M for).","Proposal to adjourn meeting not needed; quorum and sufficient proxies already present.","Annual meeting held on May 20, 2026; no other matters submitted to vote."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-236862","json":"https://secwatch.observer/filing/0001193125-26-236862.json","markdown":"https://secwatch.observer/filing/0001193125-26-236862.md","text":"https://secwatch.observer/filing/0001193125-26-236862.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783328/000119312526236862/0001193125-26-236862-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783328/000119312526236862/d43301d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T21:12:07.552220+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}